Angiotensin-converting enzyme inhibitors (ACEi) are largely used for the prevention and treatment of cardiovascular and renal diseases [1]. The rationale supporting the use of ACEi is based on evidence of extensive activation of the renin-angiotensin-aldosterone system (RAAS) in the pathophysiology of these diseases. The mechanism of action of ACEi ( Fig. 1) is based on blockade of ACE, the enzyme responsible for the conversion of angiotensin-I into angiotensin-II, as well as for the degradation of several hemodynamically active peptides including bradykinin (BK).
